Press releases
- Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor
- Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
- Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
- Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
- Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
- Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism
- Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference
- Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
- Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
- Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
More ▼
Key statistics
On Tuesday, Jazz Pharmaceuticals PLC (J7Z:FRA) closed at 105.70, 11.05% above the 52 week low of 95.18 set on May 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 106.00 |
---|---|
High | 106.15 |
Low | 105.10 |
Bid | -- |
Offer | -- |
Previous close | 105.70 |
Average volume | 257.70 |
---|---|
Shares outstanding | 63.06m |
Free float | 61.31m |
P/E (TTM) | 22.02 |
Market cap | 6.73bn USD |
EPS (TTM) | 4.85 USD |
Data delayed at least 15 minutes, as of Jun 18 2024 16:15 BST.
More ▼